Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

July 2024

Clinical pathology selected abstracts

July 2024—People with sickle cell disease may undergo treatment with the medication voxelotor, which can increase hemoglobin levels and help reduce hemolysis. A clinician treating a sickle cell disease patient with voxelotor may want to know the whole blood concentration of the drug to better monitor the patient’s treatment response, inform therapy, or confirm the patient is complying with the directions for use of the drug. Voxelotor binds to the alpha subunit of hemoglobin and results in the hemoglobin molecule being more likely to stay in the oxygenated conformation. In vivo concentrations of voxelotor cannot be measured in most clinical settings. However, voxelotor has been found to cause peak splitting in common forms of hemoglobin measurement, such as capillary zone electrophoresis (CZE) and high-performance liquid chromatography (HPLC)—that is, the classic peaks for each hemoglobin species split into a peak that has bound drug and a peak that does not.

Anatomic pathology selected abstracts

July 2024—The 2022 International Society of Urological Pathology consensus conference on urinary bladder cancer working group two was tasked with providing evidence-based proposals on applying grading to noninvasive urothelial carcinoma with mixed grades; invasive urothelial carcinoma, including subtypes and divergent differentiations; and pure non-urothelial carcinomas. Studies suggested that predominantly low-grade noninvasive papillary urothelial carcinoma with focal high-grade component has an intermediate outcome between low- and high-grade tumors. However, no consensus was reached on how to define a focal high-grade component.

Molecular pathology selected abstracts

July 2024—Telomeres are repetitive DNA sequences at the end of a chromosome that protect the chromosome from damage. They are maintained in equilibrium, as continual shortening at each round of DNA replication is counterbalanced by the de novo addition of telomere sequence repeats by telomerase. Failure to maintain the length distribution leads to short telomere syndromes that manifest as age-related degenerative diseases, such as pulmonary fibrosis, immunodeficiency, and bone marrow failure. In contrast, long telomeres can predispose people to cancer. Mutations that increase telomerase expression are one of the most common cancer-associated molecular findings.

Pathology informatics selected abstracts

July 2024—The integration of machine learning models into pathology has revolutionized the field, offering new functionalities and workflows. Numerous machine learning (ML) models are commercially available, and organizations with computational pathology resources can develop their own. These models, whether or not they are imaging based, are intended to enhance clinical practice. However, no formal guidelines pertaining to verifying or validating such systems are available. Therefore, the authors proposed recommendations for evaluating ML systems that are based on evidence and literature that address, among other factors, the scope, strengths, and limitations of the technology.

Q&A column

July 2024
Q. Insulin assays traditionally have been used to work up hypoglycemia, but we are noticing more and more requests for insulin and C-peptide testing. Is there a reason for this shift? Read answer.
Q. How should a lot-to-lot formalin comparison be done? Read answer.

Newsbytes

July 2024—Earlier this summer, Danbury Hospital completed its first academic year using an integrated pathology informatics curriculum that introduced informatics exercises into seven of the pathology residency program’s 18 rotations. “The goal is for residents to learn informatics alongside the pathology workflows where they can apply it,” says Samuel Barasch, MD, medical director of cytopathology at the Danbury, Conn.-based hospital, part of the Nuvance Health Network.

Put It on the Board

July 2024—The CAP, Association for Molecular Pathology, and Society for Immunotherapy of Cancer released in June their recommendations for tumor mutational burden assay validation and reporting. The joint publication summarizes the existing knowledge and challenges related to TMB testing. The authors make 13 recommendations related to testing, reporting, and publications on TMB assays.

MARKETPLACE

TRENDING